Renal transplantation using kidneys from hepatitis C-infected donors: A review of 30-years' experience

Deirdre Sawinski; Russel E Rosenblatt; Jose Maria Morales

doi:10.1016/j.nefroe.2022.04.006

Renal transplantation using kidneys from hepatitis C-infected donors: A review of 30-years' experience

Nefrologia (Engl Ed). 2023 Mar-Apr;43(2):182-188. doi: 10.1016/j.nefroe.2022.04.006. Epub 2022 Dec 21.

Authors

Deirdre Sawinski¹, Russel E Rosenblatt², Jose Maria Morales³

Affiliations

¹ Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
² Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
³ Research Institute, Hospital 12 de Octubre, Madrid, Spain. Electronic address: jmorales@h12o.es.

PMID: 36564226
DOI: 10.1016/j.nefroe.2022.04.006

Abstract

Kidney transplantation is the optimal therapy for end-stage kidney disease but limited by the available number of organs. Using HCV+ donors, both in HCV+ and HCV- recipients, is a rational response to the organ shortage. We review the historic experience using HCV+ donors in HCV+ recipients and assess long-term results. We also discuss contemporary practices, including the transplantation of HCV-viremic kidneys into HCV- recipients with different approaches to posttransplant HCV therapy.

Keywords: DAA; DAAs; HCV; Kidney transplant; Trasplante renal; VHC.